Background:: Anemia in developing countries is multifactorial in origin. Mild viral illness,
Introduction n
Childhoodd anemia in the developing world is multifactorial in origin. It can result from a myriadd of causes, including protein-energy malnutrition, micronutrient deficiency, numerous infectiouss diseases, and hemoglobinopathies. In areas with intense perennial malaria transmission, infectionn with Plasmodium falciparum has been shown to be a major contributor to severe anemiaa and mortality in infants [1] [2] [3] . In rural western Kenya, for example, most children are bornn with hemoglobin concentrations within the normal range but experience a progressive falll in hemoglobin until the age of 6-9 months without clear improvement until the age of 12 months.. One third of children 7-12 months of age have hemoglobin concentrations less than 88 g/dL, and 50% have hemoglobin concentrations between 8.0 and 10.9 g/dL (mild anemia) [4] .. Thus a substantial proportion of older infants are in a precarious hematological state placingg them at risk of developing subsequent severe anemia with further insult.
Measless immunization with live attenuated virus has been associated with mild viral illness and transientt decreases in hemoglobin that may persist for several weeks, and mimics iron deficiency.
Thee pathophysiology is not completely understood but may include a shift in iron distribution fromm functional towards storage compartments and possibly decreased iron absorption or intake duringg the febrile phase, with adequate erythropoietin levels [5] . The changes are small in most childrenn and of no clinical consequence to the otherwise healthy child. It is unknown if children whoo are already hematologically compromised may experience a greater fall in hemoglobin.
Measless immunization with the live-attenuated virus is associated with a temporary decrease inn cellular immunity through immunologic changes that are consistent with diminished cellmediatedd orThl response (reduced production of IL-12, IFN-gamma, and T-cells) and polarization towardd humoral or antibody immunity (Th2 activation) [6] [7] [8] [9] [10] . Earlier studies have also shown reducedd reactivity to tuberculin skin tests following measles vaccination [11] [12] [13] [14] [15] which raised concernn as to whether such depression of cellular immunity may lead to increased susceptibility too tuberculosis and other infections [16] [17] [18] [19] . Cell-mediated immunity provides partial protection againstt malaria in persons living in malaria-endemic areas. This raises the question as to whether measless vaccination may increase the severity of latent infections or increase the susceptibility too new infections with Plasmodium falciparum and further the risk of childhood anemia.
Studiess of the risk of malaria during measles infection have been equivocal. One study reported aa transient flare up of malaria due to immunosuppression induced by the viral infection [19] , whereass another study reported lower malaria parasite densities during the acute stage of measless compared to healthy children [20] . The authors of the latter study hypothesized that parasitee growth is inhibited during the acute phase of measles by a direct effect of the measles viruss creating sub-optimal conditions for parasite multiplication such as fever [21] and nutrient deficienciess of zinc or iron associated with acute measles [20] .
Thesee questions are particularly relevant in measles endemic areas that also have a high malariaa transmission pressure such as in western Kenya, where infants have up to 10 infections perr year and anemia is one of the prevailing causes of death in infants [22] . If measles vaccination iss associated with increased malaria parasitemia, preventive antimalarial treatment could be providedd at the same time as the vaccination. Antimalarials that are slowly eliminated from the body,, such as sulfadoxine-pyrimethamine (SP), can provide several weeks of prophylactic protectionn from malaria [1 ] . Initial studies suggest that co-administration of SP does not interfere withh successful measles sero-conversion [1] .
Wee retrospectively analyzed data from three different studies conducted in an area with intensee perennial malaria transmission in western Kenya to examine whether live-attenuated measless vaccine is associated with an increased risk of malaria or anemia.
Methods s
StudyStudy area and population. The studies were conducted in Asembo, Bondo district, lying northeastt of Lake Victoria in Nyanza Province in western Kenya. The study site has been described inn detail before [4, 23] . Malaria is holoendemic, and transmission occurs throughout the year.
Thee prevalence of malaria parasitemia in children aged 6-24 months ranges between 60-90% dependingg on the season. The number of infective bites per person per day averages at 0.75, and reachess as high as five bites per night [24] ; however, recent large scale deployment of insecticidetreatedd bednets reduced this malaria transmission pressure [25, 26] . Sulfadoxine-pyrimethamine (SP)) replaced chloroquine as first-line drug for the treatment of uncomplicated malaria in this area inn January 1999 [27] . Studies in this area have demonstrated a high infant mortality rate of 176/ 10000 and an under five-year child mortality rate of 257/1000 live births [28] , Thee health system in Kenya is organized around the concept of a pyramid of health facilities.
Thus,, in rural areas, healthcare is provided by health centers, dispensaries and mobile clinics thatt form the base of the pyramid and are primarily responsible for preventive and primary care.. There are 15 peripheral health facilities in Asembo, and several of these provide vaccination services.. The recommended age for measles vaccination as part of the Expanded Program on Immunizationn is 9 months, but because of recent measles epidemics this age was lowered to 66 months in some areas of Kenya. During the period that these studies were conducted, measless vaccine coverage in Kenya ranged from 61% in 1998 to 74% in 2001 [29] , but the coveragee in the study area in western Kenya was unknown.
StudyStudy descriptions.
All three studies have been described in detail elsewhere [30] [31] [32] [33] . Studyy 1, cross-sectional surveys 1996-1999 [30, 31 ] : Four cross-sectional surveys were conducted overr a period of 3 years as part of a large-scale community-based randomized controlled trial of thee impact of insecticide treated bednets on morbidity and mortality in children < 5 years of age.. These four surveys included 4,922 children <5 years of age in 60 villages. Studyy 2, anemia treatment study, 2000 [32] : This study was designed to assess the efficacy and effectivenesss of daily versus twice-weekly iron supplementation in the treatment of moderate too mild anemia in 1,049 children between 2 and 59 months of age. Children were seen once att baseline and again 6 weeks later. Immunization status was collected at baseline for all children. . Studyy 3, anemia treatment study, 1999-2000 [33] : This was a randomized placebo-controlled interventionn of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatmentt of mild anemia in 525 children between 2 and 36 months of age [32] . Children were followedd twice-weekly. At each visit, a standard morbidity questionnaire was administered and thee axillary temperature recorded. At every other visit (i.e. every 4 weeks), a finger or heel prick bloodd sample (250-500 nQ was taken for determination of hemoglobin (Hb) concentrations andd the presence of malaria parasites.
Inn all three studies the information of the child's vaccination status was copied from the routinee immunization cards provided by the caretaker. The ages of children were transcribed fromm census records and vaccination cards following verbal verification with the caretaker. If a writtenn record of the date of birth was not available, the verbal information from the caregiver wass used. The year and month of birth could be determined for all children. For those children withh an unknown day of birth, the 15 th day of the month was used. Hemoglobin measurements weree assessed using a hemocue system (HemoCue® AB, Angleholm, Sweden) or an ACT 10
Coulterr Counter (Coulter Co., Florida, USA, Serial no. AD04108) (studies 2 and 3).
DataData analysis. Vaccination coverage rates are reported using the same criteria as used by the Kenyaa Expanded Programme on Immunization (KEPI), where the numerator includes all 12-23 moo children vaccinated anytime prior to the survey, using both documented and verbal history off vaccination. In Study 2, only data at baseline have been used for the current analyses. Since bothh studies 1 and 2 are cross-sectional surveys conducted on independent children, analyses havee also been performed on children pooled from studies 1 and 2 (Study 1/2). Although Studyy 3 was a cohort study, for the purpose of the current analyses, the dataset was modified suchh that for every child meeting measles vaccination criteria described below, there was one agee and treatment group-matched control. For each study, separate analyses were conducted Forr each study, children in the 'vaccinated' group are those who received measles vaccination betweenn 6-24 mo of age and had a hemoglobin measurement available within 30 days of vaccination.. The control group for each study consisted of all 6-24 mo children who had vaccinationn cards available, and had never received measles vaccination, or received it more thann 90 days prior to the interview, or they were interviewed prior to measles vaccination.
Results s
MeaslesMeasles vaccination coverage and recent immunization: 0.044 9 a adjustedd for clustering at household level, and controlling for cross-sectional survey, presence of ITN in house, andd age; b geometric mean parasite density, and ratio of geometric means measured among those with positive parasitemia; cc cumulative prevalence of reported history of any illness in the two weeks prior to the interview; d adjustedd for clustering at household level, and controlling for age; e in study 3, vaccinated and non-vaccinated childrenn are matched for age and treatment group; f paired t-test; 9 McNemar's paired test using exact method; h onlyy 32 pairs with non-missing values for MCV are included here; only one pair available where both the vaccinatedd and the matched non-vaccinated childd have parasitemia, thus cannot perform a paired t-test Studyy 1 (17), Study 2 (10), Study 3 (76). Another 996 children were available as study matched controlss per the criteria outlined in the methods. In Studies 1 and 2, where no age-matching wass performed a-priori, children who were vaccinated within the past 30 days were younger thann their non-vaccinated counterparts (Table 2) . In Study 1, there was some indication that vaccinatedd children were more likely to be of higher socioeconomic status than non-vaccinated children.. In Study 3, 41.3% of recently vaccinated children were stunted, compared to 17.4% amongg the non-vaccinated children (p=0.01). Since Study 3 was a cohort study by design, we weree also able to compare pre-vaccination hemoglobin values to the non-vaccinated group to assuree comparability between the two groups. 
Discussion n
MildMild viral infections, such as those following immunization with the attenuated measles virus aree associated with transient decrease in hemoglobin concentrations and cellular immunity [34] ,, Using data from three of our previous studies which provided immunization status, we retrospectivelyy defined if children aged 6-24 months were at increased risk of developing more severee anemia or malaria following immunization with the measles vaccine. While these studies showedd varying effects of measles vaccination on anemia, there was no indication of a clinically andd statistically significant mean decrease in hemoglobin concentration within 14 or 30 days off vaccination. Measles vaccination was also not associated with a significant increase in the presencee of moderate anemia (Hb<8 g/dL).
Wee also found no evidence that measles vaccination was associated with an increase in the oddss of clinical malaria, malaria parasitemia, or parasite densities. On the contrary, in two out off the three studies evaluated, children who had received the measles vaccine in the last 30 dayss were slightly less likely to be malaria-smear positive within 30 days of vaccination. Although thesee results were surprising, they were consistent with one previous report conducted in an areaa of Tanzania with similar high malaria transmission and in the same age range. That study indicatedd that both the prevalence of malaria and parasite density was lower during the acute stagee of measles than in healthy children [20] . The authors hypothesized that parasite growth iss inhibited during the acute phase of measles by a direct effect of the measles virus creating sub-optimall conditions for parasite multiplication such as fever [21] and nutrient deficiencies off zinc or iron associated with acute measles [20] .
Betweenn 1996 and 1998, Kenya's Expanded Programme on Immunization (KEPI) achieved a fairlyy low coverage of measles vaccination (<62%), which increased to 79% in 1999 [29] , similarr to coverage rates in many other African countries. Our studies conducted in a specific rurall population show measles vaccination coverage rates that range from 44.8% between 1996-1999,, to 58.3% and 62.7% in the studies conducted in 1999-2000. All these estimates aree lower than the national coverage rates reported by KEPI during these respective time periods.. In an effort to increase coverage to over 95% and reduce childhood mortality, The Measless Initiative, a consortium of five leading global public health organizations, has launched ann effort to vaccinate over 200 million children by the year 2005 through both mass and follow-upp campaigns in up to 36 sub-Saharan African countries including Kenya [35] .
Thee analysis in this paper is limited by its retrospective design. None-the-less, history of immunization,, clinic visits, and details on antimalarial use were reliably documented in a large proportionn of children that took part in these studies. Furthermore, in an effort to impose strict criteriaa on documented measles vaccination, a substantial number of children without vaccination cards,, though included in reporting vaccination coverage rates, were excluded from further analyses. .
Inn conclusion, our retrospective analyses do not provide observational support to the hypothesis thatt the transient decrease in hemoglobin and cellular immune response associated with the mildd infection following immunization with live attenuated measles virus enhances the risk of subsequentt severe to moderate anemia or malaria in young children.
